WO2010144140A3 - Egfr and par2 regulation of intestinal permeability - Google Patents

Egfr and par2 regulation of intestinal permeability Download PDF

Info

Publication number
WO2010144140A3
WO2010144140A3 PCT/US2010/001670 US2010001670W WO2010144140A3 WO 2010144140 A3 WO2010144140 A3 WO 2010144140A3 US 2010001670 W US2010001670 W US 2010001670W WO 2010144140 A3 WO2010144140 A3 WO 2010144140A3
Authority
WO
WIPO (PCT)
Prior art keywords
par2
egfr
regulation
intestinal permeability
steps
Prior art date
Application number
PCT/US2010/001670
Other languages
French (fr)
Other versions
WO2010144140A4 (en
WO2010144140A2 (en
WO2010144140A8 (en
Inventor
Alessio Fasano
Karen Lammers
Terez Shea-Donohue
Original Assignee
University Of Maryland, Baltimore
Goldblum, Simeon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore, Goldblum, Simeon filed Critical University Of Maryland, Baltimore
Priority to AU2010259213A priority Critical patent/AU2010259213A1/en
Priority to CN2010800318809A priority patent/CN102481362A/en
Priority to CA2765075A priority patent/CA2765075A1/en
Priority to EP10786502.4A priority patent/EP2440246A4/en
Priority to JP2012514946A priority patent/JP2012529508A/en
Publication of WO2010144140A2 publication Critical patent/WO2010144140A2/en
Publication of WO2010144140A3 publication Critical patent/WO2010144140A3/en
Publication of WO2010144140A4 publication Critical patent/WO2010144140A4/en
Priority to US13/323,100 priority patent/US20120107329A1/en
Publication of WO2010144140A8 publication Critical patent/WO2010144140A8/en
Priority to US14/470,389 priority patent/US20140363818A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method of treating an autoimmune disease, comprising the steps of increasing transepithelial electrical resistance leading to decreased cell permeability. Further provided is ajnethod of treating celiac disease in an individual in need of such treatment, comprising the steps of: administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting PAR2.
PCT/US2010/001670 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability WO2010144140A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2010259213A AU2010259213A1 (en) 2009-06-10 2010-06-10 EGFR and PAR2 regulation of intestinal permeability
CN2010800318809A CN102481362A (en) 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability
CA2765075A CA2765075A1 (en) 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability
EP10786502.4A EP2440246A4 (en) 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability
JP2012514946A JP2012529508A (en) 2009-06-10 2010-06-10 EGFR and PAR2 regulation of intestinal permeability
US13/323,100 US20120107329A1 (en) 2009-06-10 2011-12-12 EGFR and PAR2 Regulation of Intestinal Permeability
US14/470,389 US20140363818A1 (en) 2009-06-10 2014-08-27 EGFR and PAR2 Regulation of Intestinal Permeability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18566209P 2009-06-10 2009-06-10
US61/185,662 2009-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/323,100 Continuation-In-Part US20120107329A1 (en) 2009-06-10 2011-12-12 EGFR and PAR2 Regulation of Intestinal Permeability

Publications (4)

Publication Number Publication Date
WO2010144140A2 WO2010144140A2 (en) 2010-12-16
WO2010144140A3 true WO2010144140A3 (en) 2011-05-19
WO2010144140A4 WO2010144140A4 (en) 2011-07-14
WO2010144140A8 WO2010144140A8 (en) 2012-01-26

Family

ID=43309408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001670 WO2010144140A2 (en) 2009-06-10 2010-06-10 Egfr and par2 regulation of intestinal permeability

Country Status (7)

Country Link
EP (1) EP2440246A4 (en)
JP (1) JP2012529508A (en)
KR (1) KR20120031496A (en)
CN (2) CN102481362A (en)
AU (1) AU2010259213A1 (en)
CA (1) CA2765075A1 (en)
WO (1) WO2010144140A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107329A1 (en) * 2009-06-10 2012-05-03 University Of Maryland, Baltimore EGFR and PAR2 Regulation of Intestinal Permeability
WO2022019298A1 (en) 2020-07-22 2022-01-27 富士フイルム和光純薬株式会社 Method for assisting diagnosis of inflammatory bowel disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
JP2004529610A (en) * 2000-10-13 2004-09-30 ユーエイビー リサーチ ファンデーション Human anti-epidermal growth factor receptor single chain antibody
US7611480B2 (en) * 2003-04-24 2009-11-03 Levy Mark M Gastrointestinal bioreactor
AU2005248351A1 (en) * 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
RU2007145635A (en) * 2005-05-13 2009-06-20 Юниверсити Оф Мэриленд, Балтимор (Us) METHOD FOR ESTIMATING TREATMENT MODE EFFICIENCY

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALAEDINI, A. ET AL.: "Autoantibodies in celiac disease.", AUTOIMMUNITY., vol. 41, no. 1, February 2008 (2008-02-01), pages 19 - 26, XP008151138 *
BUENO, L. ET AL.: "Protease-activated receptor 2 and gut permeability: a review.", NEUROGASTROENTEROL. MOTIL., vol. 20, no. 6, June 2008 (2008-06-01), pages 580 - 587, XP008151141 *
DUERKSEN, D. R. ET AL.: "A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet.", DIG. DIS. SCI., vol. 55, no. 4, 28 April 2009 (2009-04-28), pages 1026 - 1031, XP019788364 *
FASANO, A. ET AL.: "Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.", LANCET., vol. 355, no. 9214, 29 April 2000 (2000-04-29), pages 1518 - 1519, XP005018485 *
LAMMERS, K. M. ET AL.: "Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.", GASTROENTEROLOGY., vol. 135, no. 1, July 2008 (2008-07-01), pages 194 - 204.E3., XP022823117 *
NOORBAKHSH, F. ET AL.: "Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.", J. EXP. MED., vol. 203, no. 2, 13 February 2006 (2006-02-13), pages 425 - 435, XP008151140 *
RAIMONDI, F. ET AL.: "Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation.", AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 294, no. 4, 31 January 2008 (2008-01-31), pages G906 - 913, XP008151142 *
See also references of EP2440246A4 *
THOMAS, K. E. ET AL.: "Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease.", J. IMMUNOL., vol. 176, no. 4, 15 February 2006 (2006-02-15), pages 2512 - 2521, XP009114309 *
TRIPATHI, A. ET AL.: "Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2.", PROC. NATL. ACAD. SCI. U. S. A., vol. 106, no. 39, 15 September 2009 (2009-09-15), pages 16799 - 16804, XP008151143 *
VISSER, J. ET AL.: "Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms.", ANN. N. Y. ACAD. SCI., vol. 1165, May 2009 (2009-05-01), pages 195 - 205, XP008151167 *

Also Published As

Publication number Publication date
KR20120031496A (en) 2012-04-03
WO2010144140A4 (en) 2011-07-14
CA2765075A1 (en) 2010-12-16
EP2440246A4 (en) 2013-08-28
WO2010144140A2 (en) 2010-12-16
JP2012529508A (en) 2012-11-22
WO2010144140A8 (en) 2012-01-26
CN102481362A (en) 2012-05-30
AU2010259213A1 (en) 2012-01-19
EP2440246A2 (en) 2012-04-18
CN104940927A (en) 2015-09-30

Similar Documents

Publication Publication Date Title
AU2018256579A1 (en) Methods for preparing a skin graft
NZ750754A (en) Methods of treating eosinophilic esophagitis
MX342995B (en) Methods of generating natural killer cells.
SG10201804151QA (en) Anti-egfr antibodies and uses thereof
MX2013006595A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells.
WO2014028453A3 (en) Natural killer cells and uses thereof
WO2006066244A3 (en) Method for extending lifespan and delaying the onset of age-related disease
WO2009135615A8 (en) Means for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory t-cells
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP3566663A3 (en) Orthognathic implant
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
NZ595792A (en) Antibodies specific to cadherin-17
MX2009009982A (en) Novel human anti-r7v antibodies and uses thereof.
ZA201808086B (en) Method of treating diseases
WO2012021818A3 (en) Ggf2 and methods of use
WO2013010034A3 (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
MX2011012741A (en) A supplement comprising blackcurrants or boysenberries.
MX2013002418A (en) Administration of lorcaserin to individuals with renal impairment.
TR201818784T4 (en) Immunostimulating Composition Containing An Extract of Aronia Sp. In Combination with Selenium
WO2010144140A3 (en) Egfr and par2 regulation of intestinal permeability
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2010090876A3 (en) Satiation peptide administration
NO20056193L (en) Nutritional preparation and methods for inhibiting smooth muscle cell contraction

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080031880.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10786502

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012514946

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2765075

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010259213

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 163/CHENP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127000353

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010786502

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010259213

Country of ref document: AU

Date of ref document: 20100610

Kind code of ref document: A